F bendamustine in mixture with (A) 4-hydroperoxy-cyclophosphamide (4-HC), (B) Virus Protease drug cytosine arabinoside (araC), (C) doxorubicin (DOX) and (D) methotrexate (MTX) for 4 days (DYRK2 review Namalwa and HBL-2) or 7 days (U266). Isobolograms were generated from dose-response curves of every combination as described previously [31,32]. The outcomes of data quantification and statistical evaluation are shown in Table 1. doi:ten.1371/journal.pone.0090675.gPLOS 1 | plosone.orgPurine Analog-Like Properties of BendamustineTable 1. Quantitative analysis of your mixture of bendamustine along with other drugs in lymphoid malignancies.Effects# additive/synergistic synergistic synergistic synergistic synergistic synergistic synergistic synergistic synergistic synergistic synergistic synergistic synergistic synergistic additive/synergistic synergistic additive additive additive additive additive additive additive additive additive additive additive additive additive additive additive additive antagonistic antagonistic antagonistic antagonistic additive additive additive additive additive/synergistic additive/synergistic synergistic additiveCombined drugs 4-OHCYCell lines HBL-2 B104 Namalwa UData points eight four five six 7 5 five 8 7 4 6 7 five four 7 7 eight four 4 7 6 4 five 7 7 four five 7 9 4 four 9 9 four five 7 7 4 five six 11 four 5Observed data 0.44 0.47 0.38 0,55 0.45 0.44 0.51 0.68 0.37 0.40 0.39 0.35 0.47 0.41 0.45 0.39 0.42 0.48 0.59 0.53 0.63 0.59 0.68 0.62 0.55 0.55 0.61 0.52 0.61 0.59 0.65 0.65 0.93 0.98 1.02 0.71 0.60 0.55 0.59 0.57 0.44 0.53 0.62 0.Predicted mini. 0.47 0.58 0.51 0.62 0.49 0.55 0.63 0.74 0.45 0.51 0.45 0.45 0.61 0.52 0.48 0.57 0.36 0.41 0.55 0.33 0.42 0.48 0.35 0.54 0.52 0.43 0.38 0.51 0.42 0.48 0.57 0.53 0.22 0.44 0.45 0.36 0.40 0.42 0.46 0.40 0.58 0.59 0.53 0.Predicted max. 0.81 0.82 0.79 0.75 0.83 0.79 0.80 0.86 0.92 0.93 0.78 0.82 0.89 0.74 0.84 0.78 0.90 0.83 0.77 0.85 0.86 0.81 0.78 0.84 0.86 0.66 0.72 0.57 0.87 0.84 0.80 0.95 0.80 0.75 0.68 0.68 0.74 0.71 0.77 0.72 0.81 0.88 0.79 0.Ara-CHBL-2 B104 Namalwa UGemcitabineHBL-2 B104 Namalwa UDecitabineHBL-2 B104 Namalwa UF-Ara-AHBL-2 B104 Namalwa UDoxorubicinHBL-2 B104 Namalwa UMitoxantroneHBL-2 B104 Namalwa UEtoposideHBL-2 B104 Namalwa UMethotrexateHBL-2 B104 Namalwa UVincristineHBL-2 B104 Namalwa UBortezomibHBL-2 B104 Namalwa UMean values of observed information (S.D. not shown). Mean values from the predicted minimum values for an additive impact (S.D. not shown). Mean values with the predicted maximum values for an additive effect (S.D. not shown). # General effect of drug mixture (see Components and Approaches for the method of evaluation). doi:ten.1371/journal.pone.0090675.tPLOS 1 | plosone.orgPurine Analog-Like Properties of BendamustinePLOS One particular | plosone.orgPurine Analog-Like Properties of BendamustineFigure 3. Cell cycle effects of the combination of bendamustine with 4-OHCY or cytosine arabinoside. (A) HBL-2 cells were cultured with bendamustine alone, cytosine arabinoside alone or their mixture for 48 hours. (B) HBL-2 cells have been cultured with bendamustine alone, 4-OHCY alone or their combination for 48 hours. Cell cycle profiles were obtained by flow cytometry as described in Materials and Procedures. The size on the sub-G1 fraction was calculated by analyzing DNA histograms with the ModFitLT 2.0 system. The data shown are representative of numerous independent experiments with different concentrations from the drugs. doi:ten.1371/journal.pone.0090675.gCell CultureWe examined the effect of ENT1 inhibitors on anti-cancer drugs according to previ.
